WA-KYMETA
10.3.2020 13:02:17 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com )—the communications company making mobile global—announced the commercial availability of its next generation flat panel electronically steered antenna platform, the Kymeta u8. The new u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services transforms the purchase and consumption of mobile data with an all-inclusive hardware, connectivity and services monthly subscription starting at $999. The Kymeta u8 is the world’s only commercially available flat panel electronically steered antenna built specifically for mobility and designed for the needs of both military and commercial customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005297/en/
The Kymeta u8 antenna enables complete coverage of the Ku-band with highly reliable electronic beam steering and no moving parts. It is available as an antenna, as a terminal, or in flyaway configurations, and it can be paired with Kymeta’s new satellite and hybrid satellite-cellular connectivity solutions.
Powered by top satellite service and cellular operators throughout the world, Kymeta Connect makes buying hardware, connectivity, network services, and global support as simple and predictable as buying a mobile phone plan. A variety of satellite or satellite-cellular airtime packages are available and provided in partnership with Intelsat and Cubic Telecom, among others. Customers will now have access to easily deployable and dependable mobile connectivity in places where reliable and affordable connectivity has not been available. Kymeta is also working with LEO satellite operators on technology and service collaborations as described in press announcements released during Satellite 2020.
“With our new u8 terminal paired with Kymeta Broadband connectivity and support, we are making mobile global with a fully managed, optimized, and easy to use blended service,” said Walter Berger, President and Chief Operating Officer, Kymeta. “It is a complete solution with an elegant simplicity that will be very attractive to companies who need predictable OPEX pricing for their regional mobile connectivity services. We believe this is an industry tipping point for unlocking new access to the internet in all parts of the world.”
“We look forward to expanding our successful partnership with Kymeta as they add Intelsat’s FlexMove managed service to their communications-on-the-move (COTM) connectivity solutions offerings. Working together, Kymeta and Intelsat are helping people stay connected wherever they need to be, no matter how remote or challenging the location,” said Samer Halawi, Chief Commercial Officer, Intelsat.
Kymeta’s mobile connectivity services will be available in the US, Europe, the Middle East, Asia Pacific, sub-Saharan Africa, and Oceania with services extending to future geographies in the coming months. Initial deployments will include the military, first responders, buses, vehicle fleets, small maritime vessels, ferries, trucks and trains.
Show attendees can sign up for a meeting or live driving demonstration of the Kymeta u8 by emailing marketing@Kymetacorp.com . Additionally, the Kymeta u8 video is live and available to watch at www.kymetacorp.com .
About Kymeta
Kymeta is unlocking the potential of satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for mobile connectivity. The company’s flat-panel satellite antenna, the first of its kind, and Kymeta™ Connect connectivity services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom